Sunitinib

ArtNr	HY-10255A-200mg
Hersteller	MedChem Express
CAS-Nr.	557795-19-4
Menge	200 mg
Quantity options	100 mg 10 mM/1 mL 200 mg 500 mg
Kategorie	Oncology Neuroscience Neural Signaling Cardiovascular Research Thrombosis & Hemostasis Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer Heart & Blood Cancer Renal Cancer
Typ	Inhibitors
Specific against	other
Purity	99.69
Citations	[1]Sun L, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003 Mar 27;46(7):1116-9.\|[2]Ali MM, et al. Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO J. 2011 Mar 2;30(5):894-905.\|[3]O'Farrell AM, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003 May 1;101(9):3597-605.\|[4]Mendel DB, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Can ACS Appl Mater Interfaces. 2024 Apr 16\|Acta Pharmacol Sin. 2021 Jan;42(1):108-114.\|Arch Toxicol. 2019 Jun;93(6):1697-1712. \|Autophagy. 2024 Oct 30.\|Biochem Biophys Res Commun. 2024 Aug 19:739:150568.\|Biomacromolecules. 2021 Jun 2.\|bioRxiv. 2024 Aug 8:2024.08.08.607189.\|bioRxiv. 2024 Jul 10:2024.07.09.602803.\|Biotechnol Bioeng. 2021 Sep 3.\|Blood. 2019 Oct 17;134(16):1323-1336. \|Br J Cancer. 2024 May 31.\|Cancer Lett. 2019 Apr 10;447:105-114.\|Cancer Lett. 2021 Oct 6;S0304-3835(21)00513-9.\|Cancer Lett. 2024 Jul 1:593:216963.\|Cancers (Basel). 2022, 14(16), 3917.\|Cell Death Dis. 2024 Jul 27;15(7):533.\|Cell Metab. 2021 Sep 8;S1550-4131(21)00375-2.\|Cell Rep Methods. 2023 Oct 23;3(10):100599.\|Cell Signal. 2024 Sep 20:111425.\|Chemosphere. 2022 Sep 7;136354.\|Clin Transl Med. 2025 Feb;15(2):e70231.\|EMBO J. 2021 Apr 28;e106771.\|Exp Cell Res. 2020 Aug 1;393(1):112054.\|Front Pharmacol. 2021 Mar 8;12:644342.\|Front Pharmacol. 29 April 2021.\|Heliyon. 2024 Mar 30, e28295.\|Int Immunopharmacol. 2020 Apr;81:106227.\|Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81.\|iScience. 2024 June 28.\|J Cell Mol Med. 2025 Feb;29(4):e70428.\|J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Mar 26:1237:124100.\|J Med Chem. 2016 Sep 22;59(18):8456-72. \|J Med Chem. 2019 Jul 11;62(13):6083-6101.\|J Pharm Anal. 2023 Apr 19.\|J Transl Med. 2023 Jan 9;21(1):9.\|Med Chem Res. 2017, 26(9), 2007-2014.\|Mol Clin Oncol. 2024 Jan 18.\|Mol Oncol. 2023 Nov 27.\|Nat Biomed Eng. 2018 Aug;2(8):578-588.\|Oncotarget. 2017 Nov 15;8(67):111110-111118. \|Patent. US20220064117A1.\|Patent. US20230226111A1.\|Patent. US20240238271A1.\|Patent. US20240325538A1.\|PLoS One. 2024 Nov 1;19(11):e0308647.\|Res Sq. 2024 Jun 25.\|Research Square Preprint. 2022 Feb.\|Research Square Preprint. 2022 May.\|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|Stem Cell Reports. 2017 Dec 12;9(6):1948-1960.\|Ther Adv Med Oncol. 2019 May 17;11:1758835919849757. \|Theranostics. 2018 Jul 30;8(15):4262-4278.\|Theranostics. 2021 Mar 12;11(11):5387-5403.\|Theranostics. 2019 Oct 22;9(26):8377-8391. \|Toxicol In Vitro. 2021 Mar;71:105063.\|University of Oklahoma. 2024.\|Virulence. 2022 Dec;13(1):1849-1867.\|Adv Mater. 2024 Jan 25:e2310421.\|Biochem Biophys Res Commun. 2024 Jan 18:698:149546.\|EBioMedicine. 2018 Nov;37:344-355.\|Food Chem Toxicol. 2023 Mar 25;113743.\|Harvard Medical School LINCS LIBRARY\|Methods Mol Biol. 2024:2777:191-204.\|Oncotarget. 2017 Jul 27;8(56):95116-95134. \|University of Michigan. 2021 Jun.
Smiles	O=C(NCCN(CC)CC)C1=C(NC(/C=C2C(NC3=C\2C=C(C=C3)F)=O)=C1C)C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	SU 11248
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Autophagy; IRE1; Mitophagy; PDGFR; VEGFR
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light)
Molecular Weight	398.47
Product Description	Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 20.83 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Autophagy; Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK
Isoform	PDGFRβ; VEGFR2/KDR/Flk-1
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-10255A-200mg-safety-datasheet.pdf